CF
LCTX icon

Corebridge Financial’s Lineage Cell Therapeutics LCTX Stock Holding History

Corebridge Financial’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-87,955
Closed -$39.7K – 1500
2025
Q1 		$39.7K Buy
87,955
+14,506
+20% +$8.51K ﹤0.01% 2790
2024
Q4 		$36.9K Sell
73,449
-5,544
-7% -$4.07K ﹤0.01% 2890
2024
Q3 		$71.5K Sell
78,993
-487
-0.6% -$451 ﹤0.01% 2757
2024
Q2 		$79.3K Buy
+79,480
New +$87.8K ﹤0.01% 2721

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Corebridge Financial's LCTX Position: Q2 2025 in Review

Corebridge Financial sold out of Lineage Cell Therapeutics (LCTX) in Q2 2025, closing a stake of 87,955 shares — an estimated $39.7K sold.

Corebridge Financial first reported a position in LCTX in Q2 2024 and held it in 4 quarters. The position peaked at $79.3K in Q2 2024. 129 funds tracked by Wall St. Rank hold LCTX as of Q2 2025.

  • Corebridge Financial reported no remaining Lineage Cell Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 87,955 Lineage Cell Therapeutics shares in Q2 2025, an estimated $39.7K.
  • Corebridge Financial first reported a position in Lineage Cell Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Lineage Cell Therapeutics position peaked at $79.3K in Q2 2024.
  • 129 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.